Abstract
Since the introduction of coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines, much attention has been paid to adverse reactions. Numerous cutaneous reactions are described in the literature, but less so about chronic spontaneous urticaria (CSU). CSU is described as recurrent hives with no identifiable trigger, with or without angioedema, which persists for more than 6 weeks. It can be a frustrating diagnosis for physicians and patients alike because of the difficulty in identification and management. The mainstay of CSU treatment is antihistaminergic therapy. In this case, we describe a 35-year-old woman who was newly diagnosed with CSU after receiving the Pfizer-BioNTech COVID-19 mRNA vaccine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
